The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly
| Autor: | J. A. Gilbert, J. P. Miell, Simon Aylwin, Alan McGregor, S. M. Chambers |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Antineoplastic Agents Hormonal Endocrinology Diabetes and Metabolism medicine.medical_treatment Octreotide Sensitivity and Specificity Endocrinology Internal medicine Acromegaly Medicine Humans Insulin-Like Growth Factor I Aged Retrospective Studies Predictive marker business.industry Case-control study Retrospective cohort study Middle Aged medicine.disease Somatostatin Treatment Outcome Case-Control Studies Growth Hormone Female business Adjuvant hormones hormone substitutes and hormone antagonists Nadir (topography) medicine.drug |
| Zdroj: | Clinical endocrinology. 62(6) |
| ISSN: | 0300-0664 |
| Popis: | Summary Objective In the treatment of acromegaly, a ‘test dose’ of octreotide is recommended prior to the use of depot somatostatin analogue (SSA) therapy. However, there remains no consensus regarding the criteria that predict a response to treatment. The ability to select patients who may benefit most from medical therapy is potentially of great value in clinical practice. The aim of the study was to determine the predictive value of both the nadir GH and the mean GH following an octreotide test dose in identifying patients who subsequently achieved disease remission with depot SSA therapy. Remission was defined as a mean GH |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text